FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914693199> ?p ?o ?g. }

• W2914693199 endingPage "24" @default.
• W2914693199 startingPage "18" @default.
• W2914693199 abstract "Objectives Sequential combination of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and chemotherapy has shown greater benefits than either treatment alone in non-small-cell lung cancer (NSCLC). In this follow-up of the ENSURE study, we evaluated progression-free survival (PFS) with first-line erlotinib followed by chemotherapy at progression versus the inverse treatment sequence in 175 Chinese patients with EGFR mutation-positive NSCLC. Materials and methods Forty-five of the 175 patients included in the follow-up analysis experienced progressive disease (PD). Those with PD on first-line erlotinib (n = 24) received gemcitabine/cisplatin while those who failed first-line chemotherapy (n = 21) received erlotinib until second-line PD. The primary endpoint was PFS in the crossover subpopulation. Post-hoc analysis of survival outcomes was also measured for the overall population of 175 Chinese patients. Results Among patients who crossed over at progression, PFS was comparable between those who received second-line erlotinib and those who received second-line chemotherapy (median, 26.3 months and 23.4 months, respectively; P = 0.529). Regardless of the sequence in which the therapies were administered, patients in the crossover treatment subgroup benefited from either second-line therapy after progression with a median overall survival of 51.6 months versus 23.0 months achieved among patients in the non-crossover treatment subgroup. Post-hoc biomarker analyses of Kaplan–Meier survival curves and Cox regression showed that survival benefits with either treatment sequence were similar between patients with circulating free DNA EGFR mutations in exons 19 and 21; however, those with undetectable mutations achieved significantly greater survival benefits. Conclusion In advanced EGFR mutation-positive NSCLC, first-line erlotinib followed by chemotherapy at progression demonstrated comparable PFS benefit with the inverse treatment sequence, irrespective of mutation subtype. Utilizing both EGFR-TKIs and chemotherapy, irrespective of the sequence, maximizes survival benefits for patients." @default.
• W2914693199 created "2019-02-21" @default.
• W2914693199 creator A5002096737 @default.
• W2914693199 creator A5004295637 @default.
• W2914693199 creator A5004928583 @default.
• W2914693199 creator A5006820907 @default.
• W2914693199 creator A5010738468 @default.
• W2914693199 creator A5016050402 @default.
• W2914693199 creator A5023043755 @default.
• W2914693199 creator A5027922054 @default.
• W2914693199 creator A5027984973 @default.
• W2914693199 creator A5028624269 @default.
• W2914693199 creator A5043672686 @default.
• W2914693199 creator A5045553246 @default.
• W2914693199 creator A5052876946 @default.
• W2914693199 creator A5057704753 @default.
• W2914693199 creator A5072522693 @default.
• W2914693199 creator A5074092905 @default.
• W2914693199 date "2019-04-01" @default.
• W2914693199 modified "2023-09-26" @default.
• W2914693199 title "Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study" @default.
• W2914693199 cites W1987753948 @default.
• W2914693199 cites W2019607817 @default.
• W2914693199 cites W2070059866 @default.
• W2914693199 cites W2111662961 @default.
• W2914693199 cites W2133149289 @default.
• W2914693199 cites W2160982674 @default.
• W2914693199 cites W2210071992 @default.
• W2914693199 cites W2565711919 @default.
• W2914693199 cites W2589106419 @default.
• W2914693199 cites W2623493302 @default.
• W2914693199 cites W2753391559 @default.
• W2914693199 cites W2789572592 @default.
• W2914693199 cites W2907814135 @default.
• W2914693199 cites W2975734135 @default.
• W2914693199 doi "https://doi.org/10.1016/j.lungcan.2019.01.016" @default.
• W2914693199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30885342" @default.
• W2914693199 hasPublicationYear "2019" @default.
• W2914693199 type Work @default.
• W2914693199 sameAs 2914693199 @default.
• W2914693199 citedByCount "9" @default.
• W2914693199 countsByYear W29146931992020 @default.
• W2914693199 countsByYear W29146931992021 @default.
• W2914693199 countsByYear W29146931992022 @default.
• W2914693199 countsByYear W29146931992023 @default.
• W2914693199 crossrefType "journal-article" @default.
• W2914693199 hasAuthorship W2914693199A5002096737 @default.
• W2914693199 hasAuthorship W2914693199A5004295637 @default.
• W2914693199 hasAuthorship W2914693199A5004928583 @default.
• W2914693199 hasAuthorship W2914693199A5006820907 @default.
• W2914693199 hasAuthorship W2914693199A5010738468 @default.
• W2914693199 hasAuthorship W2914693199A5016050402 @default.
• W2914693199 hasAuthorship W2914693199A5023043755 @default.
• W2914693199 hasAuthorship W2914693199A5027922054 @default.
• W2914693199 hasAuthorship W2914693199A5027984973 @default.
• W2914693199 hasAuthorship W2914693199A5028624269 @default.
• W2914693199 hasAuthorship W2914693199A5043672686 @default.
• W2914693199 hasAuthorship W2914693199A5045553246 @default.
• W2914693199 hasAuthorship W2914693199A5052876946 @default.
• W2914693199 hasAuthorship W2914693199A5057704753 @default.
• W2914693199 hasAuthorship W2914693199A5072522693 @default.
• W2914693199 hasAuthorship W2914693199A5074092905 @default.
• W2914693199 hasConcept C121608353 @default.
• W2914693199 hasConcept C126322002 @default.
• W2914693199 hasConcept C143998085 @default.
• W2914693199 hasConcept C2776256026 @default.
• W2914693199 hasConcept C2776694085 @default.
• W2914693199 hasConcept C2778087573 @default.
• W2914693199 hasConcept C2779438470 @default.
• W2914693199 hasConcept C2780258809 @default.
• W2914693199 hasConcept C2780580887 @default.
• W2914693199 hasConcept C2780739268 @default.
• W2914693199 hasConcept C2908647359 @default.
• W2914693199 hasConcept C2909325608 @default.
• W2914693199 hasConcept C50382708 @default.
• W2914693199 hasConcept C67761136 @default.
• W2914693199 hasConcept C71924100 @default.
• W2914693199 hasConcept C99454951 @default.
• W2914693199 hasConceptScore W2914693199C121608353 @default.
• W2914693199 hasConceptScore W2914693199C126322002 @default.
• W2914693199 hasConceptScore W2914693199C143998085 @default.
• W2914693199 hasConceptScore W2914693199C2776256026 @default.
• W2914693199 hasConceptScore W2914693199C2776694085 @default.
• W2914693199 hasConceptScore W2914693199C2778087573 @default.
• W2914693199 hasConceptScore W2914693199C2779438470 @default.
• W2914693199 hasConceptScore W2914693199C2780258809 @default.
• W2914693199 hasConceptScore W2914693199C2780580887 @default.
• W2914693199 hasConceptScore W2914693199C2780739268 @default.
• W2914693199 hasConceptScore W2914693199C2908647359 @default.
• W2914693199 hasConceptScore W2914693199C2909325608 @default.
• W2914693199 hasConceptScore W2914693199C50382708 @default.
• W2914693199 hasConceptScore W2914693199C67761136 @default.
• W2914693199 hasConceptScore W2914693199C71924100 @default.
• W2914693199 hasConceptScore W2914693199C99454951 @default.
• W2914693199 hasLocation W29146931991 @default.
• W2914693199 hasLocation W29146931992 @default.
• W2914693199 hasOpenAccess W2914693199 @default.
• W2914693199 hasPrimaryLocation W29146931991 @default.

• next